Stefaan W van Gool (Stefaan Van Gool, Stefaan W Van Gool)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 12

Top Venues

Biomedicines

Cancers

Expert review of anticancer therapy

Journal of neuro-oncology

IOZK

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IOZK Sep 01 2015

Germany

Leader of translational Medicine

Publications

Volker Schirrmacher, Stefaan W van Gool, Wilfried Stuecker
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution. Biomedicines 12 (4) (2024)
Volker Schirrmacher, Stefaan W van Gool, Wilfried Stuecker
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution. Biomedicines 12 (4) (2024)
Peter Van De Vliet, Tobias Sprenger, Linde F C Kampers, Jennifer Makalowski, Volker Schirrmacher, Wilfried Stücker, Stefaan W van Gool
The Application of Evidence-Based Medicine in Individualized Medicine. Biomedicines 11 (7) (2023)
Stefaan W van Gool, Jennifer Makalowski, Peter Van de Vliet, Stefanie Van Gool, Tobias Sprenger, Volker Schirrmacher, Wilfried Stuecker
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. Cancers 15 (4) (2023)
Stefaan W van Gool, Jennifer Makalowski, Peter Van de Vliet, Stefanie Van Gool, Tobias Sprenger, Volker Schirrmacher, Wilfried Stuecker
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. Cancers 15 (4) (2023)
Stefaan W van Gool, Jennifer Makalowski, Peter Van de Vliet, Stefanie Van Gool, Tobias Sprenger, Volker Schirrmacher, Wilfried Stuecker
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. Cancers 15 (4) (2023)
Johannes E Wolff, Stefaan W van Gool, Mustafa T Kutluk, Blanca Diez, Rejin Kebudi, Beate Timmermann, Miklós Garami, Jaroslav Sterba, Gregory N Fuller, Brigitte Bison, Uwe R Kordes
Final results of the Choroid Plexus Tumor study CPT-SIOP-2000. Journal of neuro-oncology 156 (3) (2022)
Stefaan W van Gool, Jennifer Makalowski, Michael Bitar, Peter Van De Vliet, Volker Schirrmacher, Wilfried Stuecker
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. Genes and immunity (2022)
Volker Schirrmacher, Tobias Sprenger, Wilfried Stuecker, Stefaan W van Gool
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit. Biomedicines 8 (8) (2020)
Stefaan W van Gool, Jennifer Makalowski, Simon Fiore, Tobias Sprenger, Lothar Prix, Volker Schirrmacher, Wilfried Stuecker
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers 13 (1) (2020)
Tobias Sprenger, Volker Schirrmacher, Wilfried Stücker, Stefaan W van Gool
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies. Expert review of anticancer therapy 20 (8) (2020)
Isabel Vogel, Bert Verbinnen, Stefaan W van Gool, Jan L Ceuppens
Regulatory T Cell-Dependent and -Independent Mechanisms of Immune Suppression by CD28/B7 and CD40/CD40L Costimulation Blockade. Journal of immunology (Baltimore, Md. : 1950) 197 (2) (2016)

Stefaan W van Gool.css-eqlu8i{font-size:small;padding-left:4px;} (Stefaan Van Gool, Stefaan W Van Gool)

Publication Activity (10 Years)

Top Topics

Top Venues

Stefaan W van Gool (Stefaan Van Gool, Stefaan W Van Gool)